Histogram analysis of 11C-methionine integrated PET/MRI may facilitate to determine the O6-methylguanylmethyltransferase methylation status in gliomas

• Published in: Nuclear medicine communications Vol. 40; no. 8; p. 850
• Main Authors: Yu, Peng, Ning, Jing, Xu, Baixuan, Liu, Jiajin, Dang, Haodan, Lin, Mu, Feng, Xiang, Grimm, Robert, Tian, Jiahe
• Format: Journal Article
• Language: English
• Published: England 01.08.2019
• Subjects: Adult; DNA Methylation; DNA Modification Methylases - genetics; DNA Repair Enzymes - genetics; Female; Glioma - diagnostic imaging; Glioma - enzymology; Glioma - genetics; Humans; Magnetic Resonance Imaging; Male; Methionine; Multimodal Imaging; Positron-Emission Tomography; Promoter Regions, Genetic - genetics; Retrospective Studies; Tumor Suppressor Proteins - genetics
• ISSN: 1473-5628
• DOI: 10.1097/mnm.0000000000001039

We evaluate the O6-methylguanylmethyltransferase (MGMT) methylation status noninvasively by analyzing radiomics features of C-methionine (MET) PET images, which may reflect the detailed biological properties of gliomas. Fifty-seven patients with histopathologically confirmed gliomas, who were initially examined with C-MET PET/MR were retrospectively enrolled. Quantitative uptake of MET was assessed using conventional, histogram and texture features. These features were compared between the two groups classified by MGMT promoter methylation status. The histogram features (Skewness and Kurtosis) of the MGMT methylated group were significantly higher than those of the MGMT unmethylated group (Skewness: 0.90 ± 0.71 vs. 0.49 ± 0.45; P = 0.01) (Kurtosis: 1.36 ± 2.30 vs. 0.08 ± 0.65; P = 0.003), but there were no significant differences in Skewness or Kurtosis between the groups in glioma-grade-matched subgroup analysis. Moreover, there was no significant difference in other features between the methylated group and unmethylated group. The histogram features (Skewness and Kurtosis) of MET PET/MRI may be two key indicators to detect MGMT methylation status in gliomas and valuable predictors for the clinical responses of patients scheduled to receive temozolomide chemotherapeutics.